Stockscreener 앱 받기
2.00
0.00%
0.00
전일 마감가:
$2.00
열려 있는:
$2
하루 거래량:
18,189
Relative Volume:
0.16
시가총액:
$5.04M
수익:
$102.80K
순이익/손실:
$-5.32M
주가수익비율:
-0.5263
EPS:
-3.8
순현금흐름:
$-5.45M
1주 성능:
+2.56%
1개월 성능:
-13.42%
6개월 성능:
-36.51%
1년 성능:
-54.49%
1일 변동 폭
$1.99
$2.12
1주일 범위
$1.90
$2.12
52주 변동 폭
$1.69
$6.90
Creative Medical Technology Holdings Inc Stock (CELZ) Company Profile
명칭
Creative Medical Technology Holdings Inc
전화
480-399-2822
주소
211 E. OSBORN RD., PHOENIX
CELZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CELZ
Creative Medical Technology Holdings Inc
|
1.99 | 5.04M | 102.80K | -5.32M | -5.45M | -3.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.43 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.99 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.49 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.35 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.20 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Creative Medical Technology Holdings Inc 주식(CELZ)의 최신 뉴스
Degenerative Disc Disease Treatment Market Size in 7MM - openPR.com
Creative Medical Technology (CELZ) Projected to Post Earnings on Friday - Defense World
Exosome Cell and Gene Therapy Market Deep Research with Forecast - openPR.com
Companies Like Creative Medical Technology Holdings (NASDAQ:CELZ) Are In A Position To Invest In Growth - Yahoo Finance
Creative Science, a CIMA Animal Health Company, Acquires Astaria Global - Yahoo Finance
Mergers & Acquisitions Tracker - Plastics News
Creative Foam buys medical supplier AccuMed from Lear - Plastics News
Venus Shines Again, ENZ To Be Delisted, SLP, CERT On Watch - RTTNews
Head-To-Head Contrast: Atara Biotherapeutics (NASDAQ:ATRA) and Creative Medical Technology (NASDAQ:CELZ) - Defense World
Exosomes Drug Market Projected To Witness Substantial Growth, - openPR.com
Longevity Health to combine with 20/20 BioLabs in all-stock deal (XAGE:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Exosomes Market Detailed In New Research Report 2025 | Bio-Techne, QIAGEN, Lonza, System Biosciences, LLC - newstrail.com
CELZ stock touches 52-week low at $1.9 amid market challenges - Investing.com Canada
CELZ stock touches 52-week low at $1.9 amid market challenges By Investing.com - Investing.com South Africa
Creative Medical Technology files to sell 1.8M shares of common stock by selling shareholders - MSN
Pre-market Movers: ICCT, CTOR, PCVX, AIM... - RTTNews
Reviewing MiNK Therapeutics (NASDAQ:INKT) & Creative Medical Technology (NASDAQ:CELZ) - The AM Reporter
Creative Medical Technology (NASDAQ:CELZ) versus Immunocore (NASDAQ:IMCR) Head to Head Comparison - Defense World
CELZ stock touches 52-week low at $1.95 amid market challenges - Investing.com Australia
CELZ stock touches 52-week low at $1.95 amid market challenges By Investing.com - Investing.com South Africa
Creative Medical Technology Holdings, Inc. (CELZ) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Creative Medical Technology (CELZ) to Release Quarterly Earnings on Friday - The AM Reporter
Is Creative Medical Technology Holdings, Inc. (CELZ) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
What is Roth Capital’s Forecast for CELZ FY2027 Earnings? - Defense World
Creative Medical Technology (CELZ) Expected to Announce Quarterly Earnings on Friday - Defense World
Creative Medical Technology Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FDA approves expanded trial for back pain cell therapy By Investing.com - Investing.com South Africa
Creative Medical Technology Holdings Secures FDA Clearance For Expanded Dosing In Back Pain Trial - Nasdaq
FDA approves expanded trial for back pain cell therapy - Investing.com India
Creative Medical Receives FDA Approval to Expand Dosing in Back Pain Trial -March 20, 2025 at 08:27 am EDT - MarketScreener
Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain - The Manila Times
Nanoparticle Drug Delivery Market Growth, Generated - openPR.com
Creative Medical Technology Holdings Inc expected to post a loss of 64 cents a shareEarnings Preview - TradingView
Game-Changing: Family-Owned Business Thrives for Over a Century - GeeksULTD
Just Revealed: Crescent Market Beaumont Family-Owned for 100+ Years - GeeksULTD
Apple Stock Forecast: Where Will It Be In 5 Years? - GeeksULTD
Revolutionary: Stem Cell Therapy Puts Creative Medical on Profit Track - GeeksULTD
Sexual Assault in South Sudan: Experts Stunned by Breakthrough Technology - GeeksULTD
Creative Medical Technology Holdings, Inc.'s (NASDAQ:CELZ) Shift From Loss To Profit - Yahoo
When Will Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Become Profitable? - Simply Wall St
Delaware Court Just Changed the Game for Big Business - GeeksULTD
Shocking: Trump Tariffs Spark Market Sell-Off - GeeksULTD
Trump Tariffs in Chaos: Markets React - GeeksULTD
Breaking: Trump Trade War Exposes Hidden Dangers - GeeksULTD
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. SEC 10-K Report - TradingView
Hyde Park Capital Advises Infiniti Medical on its Sale to CIMA Animal Health, a Portfolio Company of Incline Equity Partners - The Malaysian Reserve
Exosomes Drug Market Detailed In New Research Report 2025 | Thermo Fisher Scientific, Inc., Bio-Techne - openPR
Exosomes Market Projected To Witness Substantial Growth, 2025-2032: Bio-Techne, QIAGEN, Lonza, Miltenyi - EIN News
Creative Medical Technology secures $3.7 million through warrants By Investing.com - Investing.com Australia
Where are the Opportunities in (CELZ) - Stock Traders Daily
Creative Medical Technology Holdings Inc (CELZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Creative Medical Technology Holdings Inc 주식 (CELZ) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Finger Michael H. | Director |
Feb 18 '25 |
Sale |
5.00 |
750 |
3,750 |
1,101 |
0.52%
0.52%
자본화:
|
볼륨(24시간):